Form 4 for SPRO Spero Therapeutics, Inc.
Accepted 2021-12-29 00:00:00 ET · period of report 2021-12-27 · accession 0000899243-21-050049 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-29 | 2021-12-27 | SPRO | Mahadevia Ankit | CEO, Pres, Dir | S - Sale+OE | $14.58 | -8,000 | 144.0K | -5% | -$116.6K |
| D | 2021-12-29 | 2021-12-27 | SPRO | Mahadevia Ankit | CEO, Pres, Dir | M - OptEx | $5.90 | +8,000 | 152.0K | +6% | +$47.2K |
| D | 2021-12-29 | 2021-12-27 | SPRO | Mahadevia Ankit | CEO, Pres, Dir | M - OptEx | $0.00 | -8,000 | 486.8K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-27 | S | D | 8,000 | $14.58 | 144,036 | D | — | — | (F3) The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.77 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. (F2) Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 78,219 restricted stock units ("RSUs") held by the Reporting Person. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date. |
| 2 | Common | Common Stock | 2021-12-27 | M | A | 8,000 | $5.90 | 152,036 | D | — | — | (F2) Amount includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee. Amount also includes 78,219 restricted stock units ("RSUs") held by the Reporting Person. Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on August 26, 2022, subject to the Reporting Person's continued service through the applicable vesting date. |
| 3 | Derivative | Stock Option (Right to Buy) | 2021-12-27 | M | D | 8,000 | $0.00 | 486,809 | D | $5.90 · — to 2027-07-05 | 8,000 Common Stock | (F4) All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date. |